Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.62 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.62 |
| ▸ | CDK2 | P24941 | 13/20 | 0.62 |
| ▸ | CDK1 | P06493 | 13/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.62 |
| ▸ | CCND3 | P30281 | 6/20 | 0.62 |
| ▸ | CDK7 | P50613 | 6/20 | 0.62 |
| ▸ | CDK9 | P50750 | 6/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.62 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.62 |
| ▸ | BRAF | P15056 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.62 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.62 |
| ▸ | CCNH | P51946 | 2/20 | 0.62 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19225629 | 0.95 | CDK4 (0.69) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL19220708 | 0.94 | CDK4 (0.71) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL19220702 | 0.88 | CDK6 (0.79) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL19225627 | 0.88 | CDK4 (0.79) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL19220707 | 0.87 | CDK4 (0.62) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL13012327 | 0.85 | CDK4 (0.67) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL2487954 | 0.83 | CDK6 (0.88) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL19057207 | 0.82 | CDK6 (0.90) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL19220701 | 0.82 | CDK6 (0.79) | CDK4CDK6CDK2CDK1CCNB1 | |
| SCHEMBL3448302 | 0.82 | CDK4 (0.69) | CDK4CDK6CDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | CDK4 3/4885CDK6 2/4885CDK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.